2024-05-06 07:43:46
France, leader in research on multiple sclerosis! Early treatment, remyelination, artificial intelligence in diagnostic aid… Focus on 3 promising studies, on the occasion of World Day on May 30, 2024.
80 clinical trials from 2018, involving 5,000 patients. France is at the forefront of multiple sclerosis research. “While the therapeutic challenges are multiple, collaborative scientific organization is more essential than ever,” FCRIN4MS estimates*. This is precisely the challenge of this clinical investigation network dedicated to this neurological disease that affects 100,000 French people. On the occasion of World Day on 30 May 2024, it considers the progress of medical research and will reveal three ongoing studies.
Predicting disease impact using AI
Early treatment…
Second question? The need for early treatment to prevent or delay the appearance of the first symptoms. This is the subject of the European TERIS study, coordinated by Dr. Christine Lebrun-Frenay (University Hospital of Nice), who emphasizes the benefits of immunomodulation therapy before the first neurological symptoms are confirmed. This double-blind study of almost 100 patients with isolated radiological syndrome (IRS) predicted multiple sclerosis showed that oral treatment with Teriflunomide provides an advantage, even during the presymptomatic stage of MS.
… to prevent MS
“One of the studies showed that the treatments reduced the risk of developing MS by 80%. This is significant! “, adds Professor Gilles Edan enthusiastically. “We often think that it starts when the initial symptoms appear (sensory disturbance, loss of visual acuity, etc.). Wrong! It is the first manifestation of the disease but, in fact, when we follow the accumulation of lesions over time, we realize that it is present sometimes from adolescence. he explains. “According to some studies, thirteen is the average age at which the brain of someone with MS becomes different from other people. So it is a pediatric disease that manifests itself in adulthood. » The challenge? “We will now be able to diagnose and offer treatment to patients who do not have a suggestive clinical picture,” he is happy.
Tissue repair
Other research focuses on the development of new treatments aimed at tissue repair (remyelination) and neuroprotection. One possible way is the use of exogenous mesenchymal cells which, in addition to their immunosuppressive capacity, would be involved in neuron protection.
F-CRIN, what’s up?
Created in 2012, F-CRIN (French clinical research infrastructure network) is a network of excellence serving French clinical research. It aims to strengthen its international competitiveness, label research networks, facilitate the implementation of academic or industrial clinical trials and develop the expertise of those involved in clinical research. To date, it brings together sixteen focused clinical investigation networks “health important diseases” (Charcot’s disease, severe asthma, obesity, Parkinson’s disease, etc.).
Labeled in 2018, *FCRIN4MS brings together a group of professionals and multidisciplinary scientific experts who act to improve the management of Member States. It consists of 34 centers covering all regions.
© Stocklib zerbor
“All rights of reproduction and representation reserved. © Handicap.fr. This article was written by Cassandre Rogeret, Handicap.fr journalist.”
Themes:
#innovative #studies #France